204 related articles for article (PubMed ID: 24509506)
1. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
[TBL] [Abstract][Full Text] [Related]
2. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
3. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
[TBL] [Abstract][Full Text] [Related]
4. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
[TBL] [Abstract][Full Text] [Related]
5. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
Fraser TR; Flogaitis I; Moore AE; Hampson G
J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
[TBL] [Abstract][Full Text] [Related]
6. Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
Reid IR; Horne AM; Mihov B; Gamble GD
Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448
[TBL] [Abstract][Full Text] [Related]
7. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
11. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
12. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
[TBL] [Abstract][Full Text] [Related]
13. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
[TBL] [Abstract][Full Text] [Related]
14. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
Grey A; Bolland M; Wattie D; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2010 Oct; 25(10):2251-5. PubMed ID: 20499349
[TBL] [Abstract][Full Text] [Related]
15. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
[TBL] [Abstract][Full Text] [Related]
16. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
Sridharan M; Cheung J; Moore AE; Frost ML; Fraser WD; Fogelman I; Hampson G
Calcif Tissue Int; 2010 Nov; 87(5):398-405. PubMed ID: 20838781
[TBL] [Abstract][Full Text] [Related]
17. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study.
Popp AW; Guler S; Lamy O; Senn C; Buffat H; Perrelet R; Hans D; Lippuner K
J Bone Miner Res; 2013 Mar; 28(3):449-54. PubMed ID: 23018784
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.
Makras P; Polyzos SA; Papatheodorou A; Kokkoris P; Chatzifotiadis D; Anastasilakis AD
Clin Endocrinol (Oxf); 2013 Oct; 79(4):499-503. PubMed ID: 23452098
[TBL] [Abstract][Full Text] [Related]
19. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
20. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
